1. 99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS). Issue 1 (April 2015) Authors: Garcia-Manero, G.; Savona, M.R.; Gore, S.D.; Cogle, C.R.; Conkling, P.; Hetzer, J.; Dong, Q.; Ukrainskyj, S.M.; Skikne, B.S. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS). (April 2017) Authors: Garcia-Manero, G.; Savona, M.R.; Gore, S.D.; Scott, B.L.; Cogle, C.R.; Boyd, T.; Conkling, P.; Hetzer, J.; Dong, Q.; Kumar, K.; Ukrainskyj, S.M.; Skikne, B.S. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Early Treatment Initiation in Myelodysplastic Syndromes (MDS) Produces Higher Rate of and Earlier Transfusion Independence (TI). (April 2017) Authors: Cogle, C.R.; Reddy, S.R.; Chang, E.; Papoyan, E.; Broder, M.S.; McGuire, M. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Predictive Simulation Approach for Personalized Analysis and Treatment of Myelodysplastic Syndromes. (April 2017) Authors: Drusbosky, L.; Sayeski, P.; Vali, S.; Albitar, M.; Abassi, T.; Cogle, C.R. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗